Trondheim-based Vitroscope just closed a $7 million round. The money is for a platform that does one thing: keep living human tissue alive and observable on a lab bench [Tech.eu, November 2026].
It is a deceptively simple goal with a complex engineering and biological payoff. The company's systems combine perfusion, continuous fluid delivery, with longitudinal imaging and sensor-controlled microenvironments. The result is a stream of data from tissue that behaves more like it does inside a body, rather than the fixed, one-time snapshots that dominate preclinical research [LinkedIn]. For pharmaceutical and biotech researchers, the promise is a more physiologically relevant alternative to conventional cell cultures and animal testing.
The Hardware Wedge
Vitroscope's bet is built on hardware. Its first commercial product, vitro.alive, is a benchtop platform for studying living tissue, including drug responses and immune activity [Tech.eu, November 2026]. The company is now validating a larger, higher-throughput system called vitro.scale, with customer testing slated for 2027 and a planned launch in 2028 [Tech.eu, November 2026].
The technical wedge is the integration of three elements in a single, controlled system.
- Continuous perfusion. This mimics blood flow, delivering nutrients and removing waste to keep tissue viable for extended periods, potentially enabling direct screening of patient samples [LinkedIn].
- Longitudinal imaging. Researchers can observe immune activity, treatment response, and disease mechanisms as they unfold over time, not just at an experiment's endpoint [vitroscope.no/about].
- Sensor-controlled microenvironment. Precise control of conditions like temperature, gas, and pH aims to generate reproducible, high-content data from complex cell models [The Hub].
This integrated approach is what separates Vitroscope from simpler cell-culture systems. It is a bet that the future of early-stage drug discovery requires more dynamic, human-relevant data.
A Team Built for Deep Tech
The founding team reflects the interdisciplinary challenge. CEO Carlo Kriesi and CTO Heikki Sjöman, both PhDs from NTNU Trondheim, bring deep engineering chops from ETH Zurich, Aalto University, and stints at CERN and Stanford [vitroscope.no/about]. They began working full-time on Vitroscope in 2021 [vitroscope.no/about].
The commercial push is led by Sandra Jernström, the chief business development officer. Her background in biochemistry and cancer genetics, including a postdoc at the Karolinska Institute, grounds the company in biological research needs. She also previously co-founded Okomera, a company she helped grow from 5 to 22 employees while raising over €12 million [Technology Networks, August 2026].
| Role | Name | Key Background |
|---|---|---|
| CEO & Co-Founder | Carlo Kriesi, PhD | Mechanical engineering (ETH Zurich), PhD (NTNU), innovation at CERN [vitroscope.no/about]. |
| CTO & Co-Founder | Heikki Sjöman, PhD | Mechatronics (Aalto University, Stanford), PhD (NTNU), prior founder [vitroscope.no/about]. |
| Chief Business Development & Co-Founder | Sandra Jernström, PhD | Biochemistry, cancer genetics, postdoc (Karolinska), prior founder of Okomera [vitroscope.no/about]. |
The Funding and the Roadmap
The recent capital infusion provides a multi-year runway. The $7 million total comprises a $5 million seed round co-led by Cerberus Ventures and YZR Capital, plus $2 million in non-dilutive funding from the Research Council of Norway [Tech.eu, November 2026]. Arcas Ventures, Golden Egg Check, Devico Invest, and several angels also participated.
| Metric | Value |
|---|---|
| 2021 Seed (StartupLab) | Undisclosed USD |
| 2026 Seed (Cerberus/YZR) | 5 M USD |
| Non-Dilutive (Research Council of Norway) | 2 M USD |
The capital is earmarked for a clear, staged roadmap. The immediate focus is on scaling the commercial rollout of the vitro.alive benchtop system. The parallel, critical path is the validation of the vitro.scale system, which represents the company's shot at higher-throughput research applications. Success in 2027 customer testing is the next major milestone.
The Competitive Landscape
Vitroscope operates in a niche but growing segment of the life sciences tools market. Its stated competitors include Mimetas and Kirkstall, companies also focused on advanced organ-on-a-chip and perfusion technologies. The competitive differentiation appears to rest on Vitroscope's specific integration of real-time imaging with its perfusion systems, a combination aimed at generating temporal data, not just sustained tissue viability.
The risk is the classic one for deep-tech hardware: sales cycles are long, and displacing entrenched lab workflows is difficult. The company has not yet publicly named commercial customers or detailed deployment numbers, which is typical for an early-stage tools company but leaves its commercial traction unproven. Its answer is the staged product rollout, using the smaller vitro.alive to build a beachhead before pushing the larger-scale system.
The Next Twelve Months
For Vitroscope, 2027 is the validation year. The planned customer testing for vitro.scale will be the first external proof point for its higher-throughput ambitions. Concurrently, the company will need to demonstrate that pharmaceutical and academic labs are willing to adopt the vitro.alive platform as a new source of discovery data.
The $5 million seed from Cerberus Ventures and YZR Capital, alongside the non-dilutive grant, gives the team the resources to execute this dual-track plan. The question for the next funding round, likely a Series A in the 2028 timeframe if milestones are hit, will be whether the data generated on its platforms has started to change how early-stage research is done. Can living tissue become a new, standard source of drug discovery data? Vitroscope's $7 million is a bet that it can.
Sources
- [Tech.eu, November 2026] Vitroscope raises $7M to turn living human tissue into a new source of drug discovery data | https://tech.eu/2026/11/03/vitroscope-raises-7m-to-turn-living-human-tissue-into-a-new-source-of-drug-discovery-data/
- [vitroscope.no/about] Company About Page | https://www.vitroscope.no/about
- [LinkedIn] Company Post on Differentiation | https://www.linkedin.com/posts/vitroscope_what-makes-vitroscope-different-activity-7347952545593450496-XiYm
- [The Hub] Company Profile | https://thehub.io/startups/vitroscope
- [Technology Networks, August 2026] Why Startups Should Apply to Innovation AveNEW | https://www.technologynetworks.com/diagnostics/articles/why-startups-should-apply-to-innovation-avenew-415375